General Catalyst is a venture capital firm that provides early-stage and growth equity investments. The company provides ongoing momentum that accelerates ideas, careers, and companies toward standout success.

General Catalyst

The 7wire Ventures’ vision is to use the power of mobility, connected devices, the cloud, and sophisticated analytics to further advance industries like healthcare and education. We like to make a difference in things that matter.  The firm was founded on the concept of disrupting the status quo—supporting new ideas, technologies, approaches, and business models for solving society’s most important problems.  7wire Ventures provides funding and operating guidance to companies that challenge the “way things are done.” Through the creation of new businesses, investments in early and growth stage companies, and by complementing funds with insight and experience, we have a track record of transforming great ideas into world-class companies.

7wire Ventures

Glikvest

Wanxiang Healthcare Investments (WHI) is a corporate-backed venture group focused on investments in healthcare technologies, with an emphasis on digital health. They believe that early to growth stage healthcare businesses represent an attractive opportunity and will generally participate in Series A through Series E rounds. WHI is looking to partner with highly motivated management teams who are committed to building the next generation of healthcare technologies. They take a long-term approach to investing and seek opportunities with like-minded entrepreneurs who are committed to making a positive impact on the healthcare industry. WHI combines a flat organizational structure with a practical business approach to ensure an efficient investment process. As a corporate-backed venture group, they do not use limited partnerships and can therefore offer flexibility when it comes to investment structure and time horizon.

Wanxiang America Healthcare Investments Group

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics, and genomics.

Polaris Partners

Scale Venture Partners is a seed-stage venture capital firm focused on intelligent business software with a Scaling Platform that has helped companies like Box, Bill.com, Hubspot, Docusign, JFrog, and WalkMe move from founder-led growth to a repeatable go-to-market machine. ScaleVP partners with entrepreneurs to support accelerated growth from the first customer to market leadership.

Scale Venture Partners

Kaiser Permanente, commonly known simply as Kaiser, is an American integrated managed care consortium, based in Oakland, California, United States, founded in 1945 by industrialist Henry J. Kaiser and physician Sidney Garfield. Kaiser Permanente is made up of three distinct but interdependent groups of entities: the Kaiser Foundation Health Plan, Inc. (KFHP) and its regional operating subsidiaries; Kaiser Foundation Hospitals; and the regional Permanente Medical Groups. As of 2017, Kaiser Permanente operates in eight states (Hawaii, Washington, Oregon, California, Colorado, Maryland, Virginia, Georgia) and the District of Columbia, and is the largest managed care organization in the United States. Kaiser Permanente is one of the largest nonprofit healthcare plans in the United States, with over 12 million members. It operates 39 hospitals and more than 700 medical offices, with over 300,000 personnel, including more than 87,000 physicians and nurses. Each Permanente Medical Group operates as a separate for-profit partnership or professional corporation in its individual territory, and while none publicly reports its financial results, each is primarily funded by reimbursements from its respective regional Kaiser Foundation Health Plan entity. KFHP is one of the largest not-for-profit organizations in the United States. KP's quality of care has been highly rated and attributed to an emphasis on preventive care, its doctors being salaried rather than paid on a fee-for-service basis, and an attempt to minimize the time patients spend in high-cost hospitals by carefully planning their stay. However, Kaiser has had disputes with its employees' unions; repeatedly faced civil and criminal charges for falsification of records and patient dumping; faced action by regulators over the quality of care it provided, especially to patients with mental health issues; and faced criticism from activists and action from regulators over the size of its cash reserves.

Kaiser Permanente

Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the United States and China. Founded by Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in its chosen core areas: social media, entertainment/media, digital health, and financial technologies.  Breyer Capital actively partners with a diverse set of companies including early-stage startups building breakthrough technologies, fast growing companies, and established worldwide leading corporations. Its team enjoys helping to frame strategic investments anchored by the passion of founders and owner/operator teams, the insights of its network of world-class investors, and a conviction that artificial intelligence, machine learning, and virtual reality will transform technology and investment opportunities globally.

Breyer Capital

D1 Capital Partners is an investment firm that deploys capital in both public and private markets. It invests on behalf of investors globally, including endowments and foundations, family offices, sovereign wealth funds, outsourced CIOs, hospitals, and pensions. D1 has a fundamental and research-intensive investment strategy with a focus on medium to long-term returns. Its research centers on the consumer, business services, financial services, healthcare, industrials, real estate and technology, media, and telecom sectors.

D1 Capital Partners

OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. OM1 believes that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. The company leverages a state-of-the-art technology platform, a world-class team of scientists, clinical experts, software engineers, and a committed network of organizations to create a new standard for health outcomes information.

OM1 is a technology and data company specialized in personalized medicine, evidence generation, and RWE research using Big Data and AI. Using its proprietary PhenOM AI platform and research-grade data, OM1 provides insights and analytics to determine treatments and monitor responses. The platform also facilitates measurement of outcomes and predictive analytics, aiming to improve the precision and efficiency of healthcare services.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

OM1 Launches Three New Products Powered by Patented AI Platform to Expedite Delivery of Personalized Medicine

Medtronic

OM1, an AI and data company in personalized medicine partnered with Medtronic to study the PROPEL devices - bioabsorbable implants designed for patients with sinusitis.

OM1 is a technology and data company specialized in personalized medicine, evidence generation, and RWE research using Big Data and AI. Using its proprietary PhenOM AI platform and research-grade data, OM1 provides insights and analytics to determine treatments and monitor responses. The platform also facilitates measurement of outcomes and predictive analytics, aiming to improve the precision and efficiency of healthcare services.The company’s key solutions include 1) Real-World Data &amp; Data Networks, comprehensive data solutions that support healthcare providers in accessing and analyzing real-world data, which include specialty areas like immunology, mental health, and neuroscience and 2) PhenOM, a solution focusing on AI &amp; Predictive Medicine. This consists of a suite of AI-driven tools, including OM1 Orion, which navigates patient journeys, OM1 Lyra, which delivers personalized insights at the point of care, and OM1 polaris, a tool to enhance research and healthcare outcomes by guiding research to identify the right patients for specific health studies or treatments.Key customers and partnershipsOM1 collaborates with healthcare providers and stakeholders to implement its data-driven solutions for outcome measurement and management. The company's RWE and predictive analytics technologies are used in chronic condition management by healthcare professionals to optimize treatments and reduce costs.

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 OM1 has introduced three novel products - OM1 Orion, OM1 Lyra, and OM1 Polaris, all built on their unique PhenOM AI digital phenotyping platform. The primary aim of PhenOM is to deliver insights based on real-world evidence (RWE) using its predictive and GenAI platforms, combined with clinical data, to create tailored treatments.
 OM1 Orion is said to offer a complete perspective on disease evolution and aids in discerning patterns in disease progression and response to treatments. OM1 Lyra is a tech tool generating insights through predictions founded on clinical and patient data. OM1 Polaris enhances patient enrolment in clinical trials through the use of predicted patient data outcomes and research protocol-specific phenotypic profiles.
 OM1 is a technology and data firm located in Massachusetts, with a specialty in personalized medicine, evidence production, and RWE investigation. Utilizing their exclusive PhenOM AI platform and high-quality research data, OM1 provides valuable insights and analytics to determine appropriate treatments and surveil responses.
</div>

OM1

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless